FDA Inspection 1316756 — Frontida BioPharm Inc
The FDA completed an inspection of Frontida BioPharm Inc on Apr 2, 2026 in Philadelphia, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Apr 2, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Philadelphia, PA (United States)